نتایج جستجو برای: درجه pasi
تعداد نتایج: 42025 فیلتر نتایج به سال:
Monitoring of biological treatment efficacy for psoriasis is based on clinical evaluation and patient's quality of life. However, long-term correlation between Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) in real life has not been studied in patients treated with ustekinumab. All patients with psoriasis treated with ustekinumab at our department were includ...
Psoriasis can be classified as mild, moderate, or severe. Given the great variability in the clinical forms of the disease, many different instruments are currently used to assess severity in these patients. However, all of these methods have limitations. Currently, the most used instruments are the Psoriasis Area Severity Index (PASI), body surface area (BSA), Investigator’s Global Assessment ...
BACKGROUND Psoriasis is a common skin disease and moderate to severe psoriasis is associated with a dose-dependent risk for metabolic and cardiovascular morbidity. It has previously been speculated that women have less severe psoriasis, as men are overrepresented in psoriasis registers and consume more care. OBJECTIVE The objective of this study was to investigate, for the first time, the sex...
Psoriasis is a chronic and inflammatory dermatologic disease. Psoriasis may predispose to cardiovascular disease and diabetes. However, the role of tumor necrosis factor (TNF) inhibitor in mediating this risk is controversial. Regarding frequent use of infliximab in psoriasis, and the hypothesis that anti TNF-α treatment may increase Body Mass Index (BMI) and alter lipid profile in these patien...
MADAM, The British Journal of Dermatology recently published a review of studies of tumour necrosis factor (TNF)-a inhibitor therapy for psoriasis, expressing the findings of key studies in terms of ‘number needed to treat to benefit’ (NNTB). Use of NNTBs is a useful way to express study results, but it is important to be clear that the NNTBs presented relate to comparisons with placebo. Many s...
BACKGROUND CF101, an adenosine A3 receptor agonist, is an orally bioavailable small molecule drug presenting an anti-psoriatic effect demonstrated in a Phase 2 clinical trial in psoriasis patients. OBJECTIVE To evaluate the safety and efficacy of CF101 treatment in a Phase 2/3 study in patients with moderate to severe plaque-type psoriasis. METHODS This multicenter, double-blind...
BACKGROUND Apremilast, an oral, small-molecule phosphodiesterase 4 inhibitor, has demonstrated efficacy in patients with moderate-to-severe psoriasis. OBJECTIVE Evaluate efficacy and safety of apremilast vs. placebo in biologic-naive patients with moderate-to-severe plaque psoriasis and safety of switching from etanercept to apremilast in a phase IIIb, randomized, double-blind, placebo-contro...
BACKGROUND Psoriasis is an immune-mediated chronic inflammatory skin disorder for which several targeted biologic therapies became available in the last 10 years. Data from patients with rheumatoid arthritis revealed that dose tapering combined with tight control of disease activity is successful. For psoriasis patients the lowest effective dose of biologics needs to be determined. The objectiv...
BACKGROUND Epidermal growth factor receptors (EGFRs) are overexpressed in psoriatic keratinocytes, and regulate cell growth, proliferation and differentiation through binding to epidermal growth factor (EGF). The role of EGF and EGFRs in the pathogenesis of psoriasis and the contribution of their measurement to psoriasis management are still unknown. AIM To evaluate serum concentrations of EG...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید